Study finds how to shutdown cancer's powerful master protein
The powerful master regulatory transcription factor called Bcl6 is key to the survival of a majority of aggressive lymphomas, which arise from the B-cells of the immune system. The protein has long been considered too complex ...
Immunology
Mar 03, 2013 |
5 / 5 (6) |
0
|
Gold nanoparticles show new way to kill lymphoma without chemotherapy
How do you annihilate lymphoma without using any drugs? Starve it to death by depriving it of what appears to be a favorite food: HDL cholesterol.
Cancer
Jan 21, 2013 |
4.9 / 5 (15) |
1
|
New protein-targeting drug shows promise in early trial for patients with high-risk CLL
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...
Cancer
May 17, 2013 |
not rated yet |
0
|
Researchers discover master regulator that drives majority of lymphoma
A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein. However, a research team, led by investigators at Weill Cornell ...
Cancer
May 13, 2013 |
5 / 5 (3) |
0
|
Researchers find NSAIDs help push stem cells into bloodstream prior to transplantation
(Medical Xpress)—A team of researchers at Indiana University's School of Medicine has found that giving meloxicam, a non-steroidal anti-inflammatory drug (NSAID), to people and baboons boosts the number of haematopoietic ...
Medical research
Mar 14, 2013 |
not rated yet |
0
|
Small molecules in the blood might gauge radiation effects after exposure
Ohio State University cancer researchers have identified molecules in the bloodstream that might accurately gauge the likelihood of radiation illness after exposure to ionizing radiation.
Cancer
Feb 25, 2013 |
5 / 5 (1) |
0
|
Experimental drug combination selectively destroys lymphoma cells
Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective ...
Cancer
Feb 06, 2013 |
4.5 / 5 (2) |
0
|
Discovery of new class of damage-prone DNA regions could lead to better cancer treatments
Cancer is thought to arise from DNA damage at fragile sites in the genome. A study published by Cell Press on January 24th in the journal Cell reveals a new class of fragile sites that contributes to DNA ...
Cancer
Jan 24, 2013 |
5 / 5 (1) |
0
|
Epigenomic abnormalities predict patient survival in non-Hodgkins lymphoma
Think of the epigenome like a giant musical mixing board, turning up or down the expression of various genes. A University of Colorado Cancer Center study published today in the journal PLOS Genetics shows that in cancer ...
Genetics
Jan 10, 2013 |
not rated yet |
0
|
New pill holds promise for fewer side effects in treating leukemia
(Medical Xpress)—An international team of researchers has developed a new anti-cancer drug that holds promise as a therapy that fights cancer while causing fewer side effects than current medicines. The ...
Cancer
Jan 07, 2013 |
5 / 5 (3) |
0
|
New technique catalogs lymphoma-linked genetic variations
(Medical Xpress)—As anyone familiar with the X-Men knows, mutants can be either very good or very bad—or somewhere in between. The same appears true within cancer cells, which may harbor hundreds of mutations that set ...
Cancer
Dec 27, 2012 |
5 / 5 (1) |
0
|
Cellular fuel gauge may hold the key to restricting cancer growth
Researchers at McGill University have discovered that a key regulator of energy metabolism in cancer cells known as the AMP-activated protein kinase (AMPK) may play a crucial role in restricting cancer cell growth. AMPK acts ...
Cancer
Dec 27, 2012 |
5 / 5 (2) |
0
|
Novel test identifies patients most likely to benefit from ALK inhibition therapy
Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients ...
Medical research
Dec 12, 2012 |
not rated yet |
0
|
Novel drug therapy targets aggressive form of non-Hodgkin's lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell – DLBCL ...
Cancer
Dec 10, 2012 |
not rated yet |
0
|
Pathway identified in human lymphoma points way to new blood cancer treatments
A pathway called the "Unfolded Protein Response," or UPR, a cell's way of responding to unfolded and misfolded proteins, helps tumor cells escape programmed cell death during the development of lymphoma.
Cancer
Nov 21, 2012 |
not rated yet |
0
|
